Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial

Holmes, David R.; Reddy, Vivek Y.; Turi, Zoltan G.; Doshi, Shephal K.; Sievert, Horst; Buchbinder, Maurice; Mullin, Christopher M.; Sick, Peter

doi:10.1016/s0140-6736(09)61343-x

Cited by 1,897 publications

(1,672 citation statements)

References 47 publications

Supporting

Mentioning

1,552

Contrasting

Unclassified

Order By: Relevance

“…Nie można w związku z tym zalecać leczenia przeciwpłytkowego w celu prewencji udaru mózgu u pacjentów z AF. [449][450][451]. Te dane wskazują, że zamykanie LAA było nie gorsze niż leczenie za pomocą VKA pod względem zapobiegania udarom mózgu u pacjentów z AF z grupy umiarkowanego ryzyka udaru, z możliwością mniejszej częstości występowania krwawień u pacjentów, u których uzyskano dane z dłuższej obserwacji [452,453].…”

Section: Leczenie Przeciwpłytkowe Jako Postępowanie Alternatywne W Stunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,332

4,193

View full text Add to dashboard Cite

Section: Leczenie Przeciwpłytkowe Jako Postępowanie Alternatywne W Stunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,332

4,193

View full text Add to dashboard Cite

“…The 4-year results of the PROTECT AF trial suggested that elimination of the LAA was superior to anticoagulation for the composite endpoint of cardiovascular death, all stroke, and systemic embolization. 1313,1314 …”

Section: Section 12: Surgical and Hybrid Af Ablationmentioning

confidence: 99%

2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design

Calkins,

Kuck,

Cappato

et al. 2012

Heart Rhythm

1,750

1,461

View full text Add to dashboard Cite

“…Watchman sustav je ispitivan u studiji PROTECT AF u kojem je viπe od 700 bolesnika s nevalvularnom FA bilo randomizirano u omjeru 2:1 bilo za ureaj (s gore navedenom antikoagulantnom i antiagregacijskom terapijom) ili dugoroËnu upotrebu varfarina (vrijednost INR 2.0 do 3.0). 10 Bila je dizajnirana kao studija neinferiornosti. Kriteriji za ukljuËivanje su bili bolesnici s paroksizmalnom, perzistentninom ili permanentnom FA i svi su bolesnici imali bodove po ljestvici CHADS2 ≥1.…”

Section: Watchman Sustavunclassified

“…The Watchman device was evaluated in the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF) trial in which over 700 patients with non-valvular AF were randomly assigned in a 2 : 1 ratio to either the device (with the above antithrombotic regimen) or to long term warfarin (international normalised ratio 2.0 to 3.0). 10 It had a non-inferiority design. Inclusion criteria allowed for patients with paroxysmal, persistent, or permanent AF and all patients had a CHADS2 score ≥1.…”

Section: Watchman Devicementioning

confidence: 99%

Almanac 2013: novel non-coronary cardiac interventions

Meier

Franzen²,

Lansky³

2013

Cardiol Croat.

View full text Add to dashboard Cite

SAAEETAK:Aktualne inovacije u intervencijskoj kardiologiji dramatiËno su proπirile terapijske moguÊnosti za srËa-ne bolesnike. Intervencijska kardiologija viπe nije ograniËena na lijeËenje koronarne bolesti srca veÊ je moguÊe lijeËiti bolesti zalistaka, raditi na prevenciji moaedanog udara, lijeËenju arterijske hipertenzije, itd. Jedna od najvaaenijih novih moguÊnosti lijeËenja je perkutano lijeËenje aortne stenoze (transkateterska implantacija aortne valvule), buduÊi da je bolest aortne valvule vrlo Ëest problem u bolesnika starije aeivotne dobi, a mnogi od njih imaju visok rizik od operacije. Isto tako, mitralna regurgitacija je Ëesto povezana s pojavom komorbiditeta koji Ëine operaciju visokoriziËnom. MitraClip je obeÊavajuÊe perkutano alternativno rjeπenje za kirurπki popravak ili zamjenu srËanog zaliska. Ostali postupci koji se spominju u ovom preglednom Ëlanku su perkutano zatvaranje aurikule lijevog atrija kao nefarmakoloπka terapija za prevenciju moaedanog udara, renalna denervacija za rezistentnu arterijsku hipertenziju. U ovom se Ëlanku pojaπnjavaju osnovni principi ovih postupaka, najvaaenije kliniËke studije uz dodatne kliniËke podatke o svakom od njih. KLJU»NE RIJE»I: intervencijska kardiologija, intervencijski zahvati na zaliscima. SUMMARY:Recent innovations in interventional cardiology have dramatically expanded the therapeutic options for patients with cardiac conditions. Interventional cardiology is no longer limited to the treatment of coronary artery disease but allows also treatment of valvular disease, stroke prevention, hypertension, etc. One of the most important new treatment options is the percutaneous treatment for aortic valve stenosis (transcatheter aortic valve implantation), since aortic valve disease is a rather common problem in elderly patients, with many of them at high risk for surgery. Similarly, mitral regurgitation is often associated with comorbidities which make surgery high risk. The MitraClip is a promising percutaneous alternative to surgical valve repair or replacement. Other procedures discussed in this review are the percutaneous left atrial appendage closure as a non-pharmacologic therapy to prevent strokes, and renal denervation for resistant hypertension. This review explains the basic principles of these procedures, the most important clinical evidence, and also provides additional recent clinical data on each of these them.

show abstract

Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial

Cited by 1,897 publications

References 47 publications

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design

Almanac 2013: novel non-coronary cardiac interventions

Contact Info

Product

Resources

About